• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

异基因骨髓移植后的长期生理副作用。

Long-term physiological side effects after allogeneic bone marrow transplantation.

机构信息

Centre Hospitalier et Universitaire de Nantes, Hématologie Clinique, Nantes, France.

出版信息

Hematology Am Soc Hematol Educ Program. 2010;2010:229-36. doi: 10.1182/asheducation-2010.1.229.

DOI:10.1182/asheducation-2010.1.229
PMID:21239799
Abstract

Allogeneic bone marrow transplantation (allo-BMT) or stem cell transplantation has the potential to cure a significant proportion of patients with otherwise fatal diseases. At present, immediate survival is no longer the sole concern after allo-BMT, because many patients can survive the acute complications of the procedure and remain free of their original disease for several years. Although long-term allo-BMT survivors generally enjoy good health, for many others cure or control of the underlying disease is not accompanied by full restoration of health. The long-term physiologic effects after allo-BMT include nonmalignant organ or tissue dysfunction; changes in quality of life; infections related to delayed, or abnormal, immune reconstitution; and secondary cancers. These long-term complications and the features of chronic graft-versus-host disease (GVHD) symptoms are heterogeneous in nature, time of onset, duration, and severity. The underlying origin of these complications is often multifactorial, with chronic GVHD being the most challenging risk factor. The main aims of this review are to present transplant physicians and health care providers with an overview of these malignant and nonmalignant late complications, with a special focus on chronic GVHD. A close partnership between the transplant center, organ-specific specialties, and local primary care providers is a key component of preventive medicine. The patient can play a major role through engagement in health maintenance behaviors.

摘要

异基因骨髓移植(allo-BMT)或干细胞移植有可能治愈很大一部分 otherwise fatal diseases 的患者。目前,allo-BMT 后立即存活已不再是唯一关注的问题,因为许多患者可以在手术的急性并发症后存活下来,并在数年中保持无原发病。尽管 allo-BMT 的长期幸存者通常身体健康,但对许多其他人来说,疾病的治愈或控制并不伴随着健康的完全恢复。allo-BMT 后的长期生理影响包括非恶性器官或组织功能障碍;生活质量的变化;与延迟或异常免疫重建相关的感染;以及继发性癌症。这些长期并发症和慢性移植物抗宿主病(GVHD)症状的特征在性质、发病时间、持续时间和严重程度上具有异质性。这些并发症的根本原因往往是多因素的,慢性 GVHD 是最具挑战性的危险因素。本综述的主要目的是向移植医生和医疗保健提供者介绍这些恶性和非恶性晚期并发症的概述,特别关注慢性 GVHD。移植中心、器官特异性专业和当地初级保健提供者之间的密切合作是预防医学的关键组成部分。患者可以通过参与健康维护行为发挥重要作用。

相似文献

1
Long-term physiological side effects after allogeneic bone marrow transplantation.异基因骨髓移植后的长期生理副作用。
Hematology Am Soc Hematol Educ Program. 2010;2010:229-36. doi: 10.1182/asheducation-2010.1.229.
2
A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.相关供体外周血与骨髓移植的比较:迟发性慢性移植物抗宿主病和感染的重要性。
Biol Blood Marrow Transplant. 2003 Jan;9(1):52-9. doi: 10.1053/bbmt.2003.50000.
3
High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases.血液系统疾病异基因骨髓移植长期存活者中内分泌功能障碍的高患病率。
Cancer. 2002 Sep 1;95(5):1076-84. doi: 10.1002/cncr.10773.
4
Health status, late effects and long-term survivorship of allogeneic bone marrow transplantation: a retrospective study.异基因骨髓移植的健康状况、远期效应及长期生存情况:一项回顾性研究。
Intern Med J. 2014 Feb;44(2):139-47. doi: 10.1111/imj.12336.
5
[CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].[用于儿童白血病治疗的非T细胞去除单倍体相合骨髓移植中预防移植物抗宿主病的CD25单克隆抗体]
Zhonghua Er Ke Za Zhi. 2004 Apr;42(4):294-8.
6
Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.采用供体外周血淋巴细胞对骨髓移植后复发白血病进行异基因细胞治疗。
Exp Hematol. 1995 Dec;23(14):1553-62.
7
[Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].[基因修饰表达sTNFR I的未成熟树突状细胞对异基因骨髓移植小鼠移植物抗宿主病(GVHD)和移植物抗白血病(GVL)的影响]
Zhonghua Xue Ye Xue Za Zhi. 2012 Feb;33(2):88-93.
8
Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation.异基因和自体造血干细胞移植后骨质流失的机制
J Bone Miner Res. 1999 Mar;14(3):342-50. doi: 10.1359/jbmr.1999.14.3.342.
9
Idiopathic pneumonia syndrome in mice after allogeneic bone marrow transplantation.异基因骨髓移植后小鼠的特发性肺炎综合征
Am J Respir Cell Mol Biol. 1998 Feb;18(2):235-42. doi: 10.1165/ajrcmb.18.2.2988.
10
Impact of stem cell source on allogeneic stem cell transplantation outcome in hematological malignancies.干细胞来源对血液系统恶性肿瘤异基因干细胞移植结局的影响。
Vojnosanit Pregl. 2011 Dec;68(12):1026-32.

引用本文的文献

1
Long-term health outcomes of allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植的长期健康结局
Front Oncol. 2023 Apr 12;13:1175794. doi: 10.3389/fonc.2023.1175794. eCollection 2023.
2
Investigating and Supporting Patient and Caregiver Sensemaking in Complex Medical Decisions Using Participatory Design.运用参与式设计在复杂医疗决策中探究并支持患者及照护者的意义建构
MDM Policy Pract. 2023 Apr 10;8(1):23814683231164988. doi: 10.1177/23814683231164988. eCollection 2023 Jan-Jun.
3
Endocrine sequelae of hematopoietic stem cell transplantation: Effects on mineral homeostasis and bone metabolism.
造血干细胞移植的内分泌后遗症:对矿物质稳态和骨代谢的影响。
Front Endocrinol (Lausanne). 2023 Jan 12;13:1085315. doi: 10.3389/fendo.2022.1085315. eCollection 2022.
4
Pediatric Vulvovaginal Graft-Versus-Host Disease: A Retrospective Cohort Study and Literature Review.儿科外阴阴道移植物抗宿主病:回顾性队列研究和文献复习。
J Pediatr Adolesc Gynecol. 2022 Oct;35(5):552-557. doi: 10.1016/j.jpag.2022.04.005. Epub 2022 Apr 25.
5
Patient and Provider Perspectives on the Impacts of Unpredictability for Patient Sensemaking: Implications for Intervention Design.患者与医疗服务提供者对不可预测性对患者意义构建的影响的看法:对干预设计的启示
J Patient Exp. 2022 Mar 29;9:23743735221089460. doi: 10.1177/23743735221089460. eCollection 2022.
6
Late follow-up of genital and ophthalmologic chronic graft-vs-host disease in females after allogeneic stem cell transplantation.异基因造血干细胞移植后女性生殖器和眼科慢性移植物抗宿主病的随访。
Acta Obstet Gynecol Scand. 2022 Mar;101(3):364-373. doi: 10.1111/aogs.14308. Epub 2021 Dec 28.
7
Managing Endocrine Disorders in Adults After Hematopoietic Stem Cell Transplantation.造血干细胞移植后成人内分泌疾病的管理
Clin Hematol Int. 2019 Sep 24;1(4):180-188. doi: 10.2991/chi.d.190917.001. eCollection 2019 Dec.
8
Pentaglobin Efficacy in Reducing the Incidence of Sepsis and Transplant-Related Mortality in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Retrospective Study.五聚球蛋白在降低接受造血干细胞移植的儿科患者败血症发病率和移植相关死亡率方面的疗效:一项回顾性研究。
J Clin Med. 2020 May 24;9(5):1592. doi: 10.3390/jcm9051592.
9
Late Complications of Allogenic Stem Cells Transplantation in Leukaemia.白血病同种异体干细胞移植的晚期并发症
Tissue Eng Regen Med. 2018 Sep 6;16(1):1-9. doi: 10.1007/s13770-018-0157-3. eCollection 2019 Feb.
10
How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.伊布替尼,一种用于治疗 B 细胞恶性肿瘤的药物,如何成为美国食品药品监督管理局批准的二线治疗药物,用于治疗类固醇难治性慢性移植物抗宿主病。
Blood Adv. 2018 Aug 14;2(15):2012-2019. doi: 10.1182/bloodadvances.2018013060.